Everything drug pricing and policy, every day
And Lilly and Novo weigh in on the early days of CMS’ Bridge program
And four studies examining everything from 340B to orphan drug incentives
And are there hints that the Bridge program is boosting GLP-1 scripts?
And the latest lawsuit pushing back on a new Lilly 340B is a great example of “safety-net cosplay”
It's a short Curve in hopes that you're enjoying a long weekend
And no one really thinks the tariff proposal is likely to achieve the goal of onshoring manufacturing, either
